The aim of the study was to assess the safety and efficacy of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause (GSM).Women presenting with GSM and meeting study criteria were enrolled. Examinations at baseline and follow-up (3 mo after final treatment) evaluated dilator tolerance and vaginal pH. Visual analog scales were used to assess pain, vaginal burning, vaginal itching, vaginal dryness, dyspareunia, and dysuria; Vaginal Health Index scores were completed before each treatment and at follow-up; Female Sexual Function Index and Short Form 12 questionnaires were also completed. Participant satisfaction was measured on a 5-point Likert scale (1?=?very dissatisfied, 5?=?very satisfied). Women received three laser treatments, 6 weeks apart.Thirty women participated (mean age 58.6?±?8.8 y). None withdrew or were discontinued due to an adverse event; three were lost to follow-up. Average improvement in visual analog scale scoring was 1.7?±?3.2 for pain, 1.4?±?2.9 for burning, 1.4?±?1.9 for itching, 6.1?±?2.7 for dryness, 5.1?±?3.0 for dyspareunia, and 1.0?±?2.4 for dysuria; improvement in average Vaginal Health Index and Female Sexual Function Index scores were statistically significant (P?
View details for DOI 10.1097/GME.0000000000000700
View details for PubMedID 27404032